Diabetes Endocrinology Research Center

总体描述(由申请人提供)： 加州大学洛杉矶分校-加州大学圣迭戈分校DERC的总体使命是促进预防和治疗糖尿病的研究 糖尿病及其并发症，并最终改善糖尿病患者的生活。这 独特的中心跨越了机构边界，利用研究的能量和兴奋 这两个机构都有糖尿病、新陈代谢、内分泌学和心血管疾病方面的研究，并满足加州大学圣迭戈分校和加州大学洛杉矶分校糖尿病/内分泌学研究人员的需求，这两个研究领域是南加州这些领域研究的主要组成部分。DERC促进了这两个机构有才华的研究人员之间的互动和合作，并在吸引仅限于糖尿病研究的杰出科学家将他们的努力集中在糖尿病领域方面发挥了重要作用。我们的成员已从93人增加到136人，目前NIH、ADA和JDRF总共资助了近5000万美元。生物医学研究基地包括：核受体、细胞信号、代谢并发症、微血管并发症和P-CELL，这些基地的成员在所有领域都处于领先地位。DERC头四年的亮点包括：1)显著扩张，收购了所有核心的最先进技术；2)建立了加州大学洛杉矶分校希尔布洛姆岛研究中心(2004)；彼得·巴特勒主任，他也刚刚担任糖尿病的主编职位；3)将拉斯克奖授予我们的DERC高级教员之一罗纳德·埃文斯；4)在加州大学洛杉矶分校和加州大学圣地亚哥分校(总共8名内科科学家、8名基础科学家和6名临床医生)大量招聘糖尿病/内分泌学教师，5)史蒂文·切斯勒(USCD)在全国P&F竞赛中获得最高P&F分数；6)在Glass、Olefsky和Rosenfeld博士之间建立了一个新的计划项目赠款，重点研究炎症、巨噬细胞和胰岛素抵抗，题为“控制巨噬细胞-脂肪细胞相互作用和胰岛素抵抗的基因网络”。核心：转基因和基因敲除小鼠、小鼠表型鉴定、转录基因组学、人类遗传学 由核心支持的大量出版物判断，由经社文中心成员使用。 由于科学理论和我们成员的兴趣，炎症核心最近成立了。UCLA-UCSD DERC已成为糖尿病/内分泌学研究的关键焦点和重要催化剂，以及教育、培训、提高对糖尿病护理研究的认识和促进转化研究的资源。未来的方向将继续争取两个机构的研究人员无缝整合，提高DERC的技术和研究能力，促进参与卫生服务研究的转化研究活动，并可能与纳米技术合作。

DESCRIPTION, OVERALL (provided by applicant): The overall mission of the UCLA-UCSD DERC is to foster research in the prevention and treatment of diabetes and its complications and ultimately to improve the lives of patients with diabetes. This unique Center crossed institutional boundaries to harness the energy and excitement of research in diabetes, metabolism, endocrinology, and cardiovascular disease in both institutions and to serve the needs of diabetes/endocrinology researchers at UCSD and UCLA, which comprises the major component of research in these fields in Southern California. The DERC has fostered interaction and collaboration between talented researchers at both institutions and has played an important role in bringing outstanding scientists only peripherally involved in diabetes research to focus their efforts in the diabetes arena. Our membership has grown from 93 to 136 with combined current NIH, ADA and JDRF funding of nearly $ 50 M. Biomedical Research Bases consist of: Nuclear Receptors, Cell Signaling, Metabolism Complications, Microvascular Complications, and p-cell with leaders in all fields as members of these Bases. The highlights during the first four years of the DERC include: 1) A marked expansion with the acquisition of state-of-the-art technology for all Cores, 2) Establishment of the UCLA Hillblom Islet Research Center (2004), Director Peter Butler, who has also just assumed the editor-in-chief position of Diabetes, 3) Designation of the Lasker Award to Ronald Evans, one of our Senior DERC faculty, 4) Substantial recruitment of Diabetes/Endocrinology based faculty at both UCLA-UCSD (collectively 8 physician scientists, 8 basic scientists and 6 clinicians), 5) Achievement of the highest ranking P&F score in national P&F competition by Steven Chessler (USCD), 6) Establishment of a new Program Project grant among Drs. Glass, Olefsky, and Rosenfeld, focused on the study of inflammation, macrophages, and insulin resistance, entitled "Gene Networks Controlling Macrophage-Adipocyte Interactions and Insulin Resistance." The Cores: Transgenic and Knockout Mouse, Mouse Phenotyping, Transcriptional Genomics, Human Genetics have been heavily used by DERC members as judged by the extensive number of publications supported by the Cores. Because of scientific rationale and interest of our members, the Inflammation Core was recently established. The UCLA-UCSD DERC has emerged as a key focal point and important catalyst of diabetes/endocrinology research, as well as a resource for education, training, raising awareness of diabetes care research and promoting translational research. Future directions will continue to strive for seamless integration of researchers at both institutions, to enhance technology and research capability in the DERC, to promote translational research activity with involvement of health services research, and to potentially partner with nanotechnology.